Search

Displaying results 3331 - 3340 of 7687 in total
  1. Drug

    Protocatechualdehyde

    go.drugbank.com/drugs/DB11268
    Approved

    Protocatechualdehyde possesses antiproliferative and pro-apoptotic properties against human breast cancer cells and colorectal cancer cells by reducing the expression of pro-oncogenes β-catenin and cyclin D1

  2. Drug

    Sulthiame

    go.drugbank.com/drugs/DB08329
    Approved

  3. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines.

  4. Drug

    Obinepitide

    go.drugbank.com/drugs/DB05045
    Experimental

    These hormones are known to play a role in the regulation of food intake and appetite in man as satiety signal from the GI-tract to the CNS.

  5. Drug

    Etidocaine

    go.drugbank.com/drugs/DB08987
    Approved

    It is an injectable local anesthetic during surgery, labor, and delivery. Etidocaine has a long duration of activity, but has the main disadvantage of increased bleeding during oral surgery.

  6. Drug

    Maprotiline

    go.drugbank.com/drugs/DB00934
    Approved

    Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and...

  7. Drug

    Paliroden

    go.drugbank.com/drugs/DB05454
    Investigational

    Paliroden is an orally active neurotrophic, non-peptidic compound that activates synthesis of endogenous neurotrophines.

  8. Drug

    R450

    go.drugbank.com/drugs/DB05469
    Experimental

    R450 is an alpha 1 antagonist that acts to tighten the muscle tone in the bladder. It is being considered for treatment of stress-related urinary incontinence.

  9. Drug

    T-5224

    go.drugbank.com/drugs/DB05998
    Experimental

    T-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.

  10. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission.